Agalsidase beta Completed Phase 2 Trials for Fabry's Disease Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01196871Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease
NCT01363492Safety Study of Replagal® Therapy in Children With Fabry Disease
NCT00074958A Study of Fabrazyme in Pediatric Patients With Fabry Disease
NCT00084084Replagal Enzyme Replacement Therapy for Children With Fabry Disease
NCT00196716A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00071877An Open-Label Clinical Trial of Replagal Enzyme Therapy in Children Ages 7-17 Years With Fabry Disease
NCT00075244Alternative Dosing and Regimen of Replagal to Treat Fabry Disease
NCT00068107Dosing Study of Replagal in Patients With Fabry Disease